A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT07281937 on ClinicalTrials.gov · last registry update 2026-08-17
Finished 23 July 2026, after enrolling 206 people. Primary outcome, as filed: Mean percent change from baseline in body weight. ecnoglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P2
- Drug
- ecnoglutide
- Sponsor
- Verdiva Bio Dev Limited
- Sponsor type
- Industry
- Enrollment
- 206
- Started
- 2025-11-25
- Primary completion
- 2026-07-23 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Mean percent change from baseline in body weight
Conditions studied
Obesity · Overweight
Every field above is taken directly from the registry record. See all detected changes across the class, or the ecnoglutide page for this molecule’s full trial and approval history.